Aortic Valve Stenosis Clinical Trial
Official title:
Protection of Heart, Brain and Kidney by Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation - a Randomized, Single-blind Study
Transcatheter aortic valve implantation (TAVI) has rapidly been adopted into clinical practice, but concerns have been raised regarding periprocedural complications like e.g. myocardial injury, stroke or acute kidney injury. Remote ischemic preconditioning (RIPC) with upper limb ischemia/reperfusion provides perioperative myocardial protection in patients undergoing elective coronary artery bypass surgery. The present study assesses protection of heart, brain and kidney by RIPC in patients undergoing TAVI. The study also addresses safety and clinical outcome.
- On the assumption of our recent data (Thielmann et al, Lancet 2013, 382(9892):597-604),
we performed a power analysis, revealing an estimated enrollment of 189 patients per
group. But since no true data exist regarding RIPC and TAVI, interim analysis will be
performed after 50 patients per group.
- After induction of conscious sedation or general anaesthesia, RIPC is accomplished by 3
cycles of 5 min inflation/5 min deflation of a blood pressure cuff around the left arm
to 200 mm Hg. In the placebo group, the blood pressure cuff remains uninflated for 30
min.
- Blind: study coordinators, outcome assessors, operators and treating physicians except
for the attending anaesthetist.
- Drugs used for conscious sedation: midazolam, remifentanil.
- Drugs used for general anaesthesia: sufentanil, etomidate, rocuronium, isoflurane.
- TAVI is performed by standard techniques using the balloon-expandable Sapien XT
(Edwards Lifesciences Inc., Irvine, California, USA) and the next-generation Sapien 3
stent-valve bioprosthesis which replaces the Sapien XT prosthesis, when CE-approved.
- Arterial blood samples are obtained prior to and after RIPC-maneuver/Placebo, after
aortic valve implantation and after access site closure, for biochemical analyses
focussing on ligands that have been previously implicated in conditioning protocols at
various organs. A bioassay system, consisting of a Langendorff-perfused isolated heart
with ischemia and reperfusion will be used. This bioassay system will be exposed to the
obtained arterial plasma of the patients.
- Venous blood samples are drawn before TAVI and at 1, 6, 12, 24, 48 and 72 hours after
the procedure.
- Cardiac and cerebral MRI is performed in selected patients at baseline and within the
first week after TAVI.
- On-site follow-up at 3±3 months, 12±3 months and yearly thereafter.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
| Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
| Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
| Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
| Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
| Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
| Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
| Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
| Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
| Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
| Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
| Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
| Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
| Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
| Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
| Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
| Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
| Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
| Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|
||
| Recruiting |
NCT01683474 -
Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis
|
N/A |